KemPharm (NASDAQ:KMPH – Get Rating) will be announcing its earnings results after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.
KemPharm (NASDAQ:KMPH – Get Rating) last posted its earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). KemPharm had a positive return on equity of 7.03% and a negative net margin of 29.86%. On average, analysts expect KemPharm to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of KemPharm stock opened at $4.54 on Thursday. The stock’s 50-day moving average is $4.99 and its 200-day moving average is $6.94. KemPharm has a one year low of $4.10 and a one year high of $15.70.
Several analysts recently issued reports on KMPH shares. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a report on Thursday. StockNews.com assumed coverage on KemPharm in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, HC Wainwright raised KemPharm from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $10.00 to $11.00 in a research report on Monday, January 31st.
KemPharm Company Profile (Get Rating)
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
- Get a free copy of the StockNews.com research report on KemPharm (KMPH)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.